Rol del estado en los ensayos clínicos
Bibliographic Data
| ID | 15533305 |
|---|---|
| Authors | Pilar Mazzetti (0000-0002-4376-847X, National University of San Marcos, corresponding author), Gustavo Silva-Paredes (0000-0001-6132-2239, Escuela Nacional de Sanidad), Mario Cornejo‐Olivas (0000-0001-6313-5680, Instituto Nacional de Neurología y Neurocirugía) |
| Year | 2014 |
| Volume | 29 |
| Issue | 4 |
| Publication date | 2014-02-05 |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | Revista Peruana de Medicina Experimental y Salud Pública (JOURNAL) |
| Journal identifiers | ISSN: 1726-4634 • E-ISSN: 1726-4642 |
| Publisher | National Institute of Health of Peru (PUBLISHER • PE) |
| DOI | 10.17843/rpmesp.2012.294.396 |
| OpenAlex | W4206675199 |
| Language | ES |
| References cited | 2 |
The regulation of clinical trials by the Government is a process of continuous change and adaptation, current challenge is to ensure the safety of participants and get balance of administrative procedures. Development and regulation of clinical trials in different countries vary according to the situation, context national or international execution, determining the insufficiency of national regulation requiring review of international regulation. The aim of this publication is to present a comprehensive overview of the role of Government in the regulation of clinical trials in different realities. It includes a review of the regulation in The European Union, The United States and some Latin American countries and finally the regulation in Peru. Contemporary trends in the regulation of clinical trials, are characterized by increasing standards of quality, ensuring the safety of the participants, promote transparency, lower bureaucratic processes and strengthening ethics IRB committees in the framework of open democratic processes, involving all stakeholders in dynamic processes based on current knowledge and changing tendencies. The challenge is to promote the development of clinical trials from the government institutions (universities, research centers, institutes, hospitals, etc.) priorizing local needs including orphan drugs, prevalent and neglected diseases, and therapeutic use of active components of local native plants
Bureaucracy · Business · Clinical trial · Context (archaeology · Economic policy · European union · Government (linguistics · Government regulation · Humanities · Political science · Transparency (behavior · Biomedical Ethics and Regulation · Ethics and bioethics in healthcare · Ethics in Clinical Research · Health Systems, Economic Evaluations, Quality of Life · Law · Medicine · Philosophy · Public Administration
| Highly cited | No |
|---|